- Home
- MFIN vs KROS Comparison
MFIN vs KROS Comparison
Compare MFIN & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIN | KROS |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | 179 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.3M | 206.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MFIN | KROS |
|---|---|---|
| Price | $9.99 | $10.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $12.00 | ★ $21.86 |
| AVG Volume (30 Days) | 102.4K | ★ 313.0K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.02 | $2,751.79 |
| P/E Ratio | $6.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $9.69 |
| 52 Week High | $11.00 | $22.55 |
Technical Indicators
Market Signals| Indicator | MFIN | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 48.01 | 45.71 |
| Support Level | $9.73 | $10.14 |
| Resistance Level | $9.87 | $11.55 |
| Average True Range (ATR) | 0.30 | 0.58 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 8.62 | 13.77 |
Price Performance
Historical ComparisonAbout MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.